Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) fell 3.9% on Wednesday . The stock traded as low as $5.70 and last traded at $5.73. 759,562 shares changed hands during trading, a decline of 87% from the average session volume of 5,642,950 shares. The stock had previously closed at $5.96.
Wall Street Analyst Weigh In
Separately, Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $6.00 and gave the stock a "neutral" rating in a report on Monday, April 29th.
Read Our Latest Analysis on ImmunityBio
ImmunityBio Price Performance
The company's 50-day simple moving average is $6.68 and its 200-day simple moving average is $5.23. The company has a market cap of $3.87 billion, a price-to-earnings ratio of -5.14 and a beta of 1.03.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.03 million. Equities analysts predict that ImmunityBio, Inc. will post -0.75 EPS for the current fiscal year.
Institutional Investors Weigh In On ImmunityBio
A number of hedge funds have recently added to or reduced their stakes in IBRX. Vanguard Personalized Indexing Management LLC bought a new stake in ImmunityBio in the third quarter valued at $37,000. Blair William & Co. IL lifted its stake in ImmunityBio by 200.7% in the third quarter. Blair William & Co. IL now owns 162,462 shares of the company's stock valued at $275,000 after buying an additional 108,431 shares during the last quarter. WINTON GROUP Ltd bought a new stake in ImmunityBio in the third quarter valued at $26,000. Rathbones Group PLC acquired a new position in shares of ImmunityBio during the third quarter valued at $124,000. Finally, Armistice Capital LLC acquired a new position in shares of ImmunityBio during the third quarter valued at $5,874,000. 8.58% of the stock is currently owned by institutional investors.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
